PMID- 28688781
OWN - NLM
STAT- MEDLINE
DCOM- 20180319
LR  - 20180402
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 35
IP  - 34
DP  - 2017 Aug 3
TI  - Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with
      underlying medical conditions.
PG  - 4321-4329
LID - S0264-410X(17)30878-2 [pii]
LID - 10.1016/j.vaccine.2017.06.081 [doi]
AB  - BACKGROUND: Streptococcus pneumoniae is a leading cause of vaccine-preventable
      disease in children under 5years. Immunocompromised children and those with
      underlying diseases are at increased risk of severe complications from
      vaccine-preventable infections. We studied the humoral immune response to the
      13-valent pneumococcal conjugate vaccine (PCV13) in children with HIV-infection, 
      kidney or lung disease and compared this to the response in healthy control
      children. METHODS: Children aged 12-71months with underlying conditions including
      HIV-infection and those with kidney and lung diseases (at-risk children), and a
      healthy control group were vaccinated with PCV13. The at-risk children received
      two doses of PCV13 and the controls received one dose. Serotype-specific
      antibodies for all PCV13 serotypes were measured by a luminex-based enzyme
      immunoassay at baseline and post-vaccination. RESULTS: After the first PCV13
      dose, the fold-increase in serotype-specific antibody geometric mean
      concentrations (GMCs) from baseline and the percentage of participants with
      >/=4-fold-increase in antibody concentrations was similar between the control and
      at-risk children. GMCs were, however, lower for three of the 13 serotypes in
      HIV-infected children, higher for serotype 6B in children with kidney disease and
      higher for serotypes 6B and 14 in children with lung disease. After second
      vaccine dose HIV-infected children had an increase in GMCs from post-first dose
      for nine serotypes but the percentage of participants with >/=4-fold-increase
      from baseline was similar post-second dose compared to post-first dose except for
      serotypes 6A and 19F. In children with kidney or lung diseases the immune
      responses after second vaccine dose were similar to post-first dose. Attenuated
      responses were observed for serotypes 3 and 19A in all study-groups, which was
      especially pronounced in the at-risk groups. CONCLUSION: All study-groups mounted
      an immune response to PCV13, with the at-risk groups having responses that were
      mostly similar to the control children.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Jallow, Sabelle
AU  - Jallow S
AD  - Department of Science and Technology/National Research Foundation: Vaccine
      Preventable Diseases, University of the Witwatersrand, Johannesburg, South
      Africa; Medical Research Council: Respiratory and Meningeal Pathogens Research
      Unit, University of the Witwatersrand, Johannesburg, South Africa; National
      Institute for Communicable Diseases: A Division of National Health Laboratory
      Service, Centre for Vaccines and Immunology, Johannesburg, South Africa.
FAU - Madhi, Shabir A
AU  - Madhi SA
AD  - Department of Science and Technology/National Research Foundation: Vaccine
      Preventable Diseases, University of the Witwatersrand, Johannesburg, South
      Africa; Medical Research Council: Respiratory and Meningeal Pathogens Research
      Unit, University of the Witwatersrand, Johannesburg, South Africa; National
      Institute for Communicable Diseases: A Division of National Health Laboratory
      Service, Centre for Vaccines and Immunology, Johannesburg, South Africa.
FAU - Madimabe, Richard
AU  - Madimabe R
AD  - Department of Science and Technology/National Research Foundation: Vaccine
      Preventable Diseases, University of the Witwatersrand, Johannesburg, South
      Africa; Medical Research Council: Respiratory and Meningeal Pathogens Research
      Unit, University of the Witwatersrand, Johannesburg, South Africa.
FAU - Sipambo, Nosisa
AU  - Sipambo N
AD  - Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic
      Hospital and Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa.
FAU - Violari, Avy
AU  - Violari A
AD  - Perinatal HIV Research Unit, Faculty of Health Sciences, University of the
      Witwatersrand, South Africa.
FAU - Kala, Udai
AU  - Kala U
AD  - Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic
      Hospital and Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa.
FAU - Petersen, Karen
AU  - Petersen K
AD  - Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic
      Hospital and Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa.
FAU - Naidoo, Sanushka
AU  - Naidoo S
AD  - Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic
      Hospital and Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa.
FAU - Verwey, Charl
AU  - Verwey C
AD  - Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic
      Hospital and Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa.
FAU - Moore, David P
AU  - Moore DP
AD  - Department of Science and Technology/National Research Foundation: Vaccine
      Preventable Diseases, University of the Witwatersrand, Johannesburg, South
      Africa; Medical Research Council: Respiratory and Meningeal Pathogens Research
      Unit, University of the Witwatersrand, Johannesburg, South Africa; Department of 
      Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital and
      Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South 
      Africa.
FAU - Nunes, Marta C
AU  - Nunes MC
AD  - Department of Science and Technology/National Research Foundation: Vaccine
      Preventable Diseases, University of the Witwatersrand, Johannesburg, South
      Africa; Medical Research Council: Respiratory and Meningeal Pathogens Research
      Unit, University of the Witwatersrand, Johannesburg, South Africa. Electronic
      address: nunesm@rmpru.co.za.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170705
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (13-valent pneumococcal vaccine)
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Pneumococcal Vaccines)
SB  - IM
MH  - Antibodies, Bacterial/blood/immunology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - HIV Infections/complications/immunology/virology
MH  - Humans
MH  - Immunity, Humoral
MH  - Immunization, Secondary
MH  - *Immunocompromised Host
MH  - Immunoenzyme Techniques
MH  - *Immunogenicity, Vaccine
MH  - Immunoglobulin G/blood/immunology
MH  - Infant
MH  - Kidney Diseases/immunology
MH  - Lung Diseases/immunology
MH  - Male
MH  - Pneumococcal Infections/*prevention & control
MH  - Pneumococcal Vaccines/administration & dosage/adverse effects/*immunology
MH  - Serogroup
MH  - Streptococcus pneumoniae/*immunology
OTO - NOTNLM
OT  - *HIV
OT  - *Kidney
OT  - *Lung
OT  - *PCV13
OT  - *Pneumococcal conjugate vaccine
OT  - *Streptococcus pneumoniae
EDAT- 2017/07/10 06:00
MHDA- 2018/03/20 06:00
CRDT- 2017/07/10 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/05/30 00:00 [revised]
PHST- 2017/06/25 00:00 [accepted]
PHST- 2017/07/10 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
PHST- 2017/07/10 06:00 [entrez]
AID - S0264-410X(17)30878-2 [pii]
AID - 10.1016/j.vaccine.2017.06.081 [doi]
PST - ppublish
SO  - Vaccine. 2017 Aug 3;35(34):4321-4329. doi: 10.1016/j.vaccine.2017.06.081. Epub
      2017 Jul 5.